Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Veracyte, Inc. ("Veracyte" or "the
NEW YORK CITY, NY / ACCESS Newswire / November 9, 2026 / VCYT shareholders are absorbing losses after Veracyte (NASDAQ:VCYT) lowered the top of its full-year 2026 revenue guidance to $593 million from $596 million on
Veracyte shares fell after its November 4, 2026 report despite $151.8 million in third-quarter revenue and a new $100 million buyback, as the market reacted to a weaker Decipher Prostate outlook. An investigation
Veracyte stock fell more than 50% after the Company reported on November 4, 2026 that Decipher Prostate volume fell short of its expectations. Levi and Korsinsky investigates into potential securities law violations.
VCYT’s stock is down more than 50%; Ademi LLP is investigating Veracyte for potential securities fraud. CLICK HERE TO JOIN MILWAUKEE, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating possible securities
Grew total revenue to $151.8 million and testing revenue to $146.4 million, representing 15% year-over-year growth Announces $100 million share repurchase program SOUTH SAN FRANCISCO, Calif., Nov. 04, 2026 (GLOBE
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced that 10 abstracts involving its Afirma thyroid test will be presented
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced it will be participating in the following investor conferences: UBS
SOUTH SAN FRANCISCO, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced new data showing that its Decipher® Prostate Genomic Classifier can
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced that six studies involving its genomic tests will be presented at the
SOUTH SAN FRANCISCO, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced that its Prosigna® Breast Risk of Recurrence (ROR) test has received coverage
SOUTH SAN FRANCISCO, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the third quarter 2026
SOUTH SAN FRANCISCO, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, announced that new findings from a retrospective ancillary analysis of the randomized
SOUTH SAN FRANCISCO, Calif., Sept. 25, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, announced today that eight studies leveraging its Decipher Prostate Genomic
SOUTH SAN FRANCISCO, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced its acquisition of Convergent Genomics. The acquisition adds
